In people with type‑1 diabetes, blood tends to clot too much and break down clots too slowly, a problem that isn’t fixed by usual diabetes meds. Giving the short peptide Vilon (Lys‑Glu) lowered these clot‑related abnormalities, sometimes almost completely, though the benefit was smaller in older patients with severe disease.

It was revealed that patients suffering from the diabetes mellitus type 1 (DM-1) on the stage of destabilization report accelerated blood coagulability, decreased content of natural anticoagulators (antithrombin III and protein C), increased concentration of fibrogene and soluble fibrinmonomer complexes and reduced fibrinolysis. The obtained data testify the development of chronic form of DIC syndrome, moreover there is a correlation between the age of the patient, the severity of the disease, insulin dose, presence and severity of the complications on the one hand and the intensity of DIC syndrome on the other hand. Generally accepted treatment of the DM-1 patients doesn't exert considerable effect on the processes of intravascular blood coagulation. Meanwhile administration of thymomimetic Vilon (Lys-Glu) in these patients significantly reduces or even totally diminishes DIC syndrome. In elderly patients with severe form of the disease the effect of Vilon on coagulative hemostasis and blood fibrinolytic activity is less pronounced.